First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers
- DOI
- 10.1080/13543784.2025.2453162
- Published
- 2025-01-20
- Container
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/13543784.2025.2453162,
title = {First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers},
author = {Hong Zhang and Wenbo Zheng and Ran Peng and Dandan Wu and Yue Hu and Tiantian Sun and Lei Gao and Yusi Liu and Li Guo and Yanhua Ding and Li Liu},
year = {2025},
journal = {Expert Opinion on Investigational Drugs},
doi = {10.1080/13543784.2025.2453162},
url = {https://doi.org/10.1080/13543784.2025.2453162}
}RIS
TY - JOUR TI - First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers AU - Hong Zhang AU - Wenbo Zheng AU - Ran Peng AU - Dandan Wu AU - Yue Hu AU - Tiantian Sun AU - Lei Gao AU - Yusi Liu AU - Li Guo AU - Yanhua Ding AU - Li Liu PY - 2025 JO - Expert Opinion on Investigational Drugs DO - 10.1080/13543784.2025.2453162 UR - https://doi.org/10.1080/13543784.2025.2453162 ER -
APA
Zhang, H., Zheng, W., Peng, R., Wu, D., Hu, Y., Sun, T., Gao, L., Liu, Y., Guo, L., Ding, Y., & Liu, L. (2025). First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2025.2453162
Source records
- crossref · retrieved 2026-09-27T05:58:12.605Z